R&D Does the answer to advancing rare disease treatment lie in r... What do 300 million people have in common? They are living with rare diseases that are defined by their scarcity within the general population.
News ADA: Lilly makes its case for oral GLP-1 orforglipron Lilly is on track to file its oral GLP-1 agonist orforglipron for type 2 diabetes next year after presenting the first phase 3 data with the drug.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face